Comparative Pharmacology
Head-to-head clinical analysis: NICORETTE versus NICOTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICORETTE versus NICOTINE.
NICORETTE vs NICOTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicotine acts as an agonist at nicotinic acetylcholine receptors, stimulating the release of neurotransmitters such as dopamine and norepinephrine, which reduces withdrawal symptoms and cravings associated with smoking cessation.
Nicotine is a nicotinic acetylcholine receptor (nAChR) agonist; binds to α4β2 and α7 subtypes in the central nervous system, causing release of dopamine and other neurotransmitters, leading to stimulation and reward effects. Also acts on peripheral nicotinic receptors affecting autonomic ganglia, neuromuscular junction, and adrenal medulla.
Nicotine replacement therapy. For smoking cessation, chewing gum: 2 mg or 4 mg piece chewed slowly for 30 minutes every 1-2 hours as needed, maximum 24 pieces/day. Transdermal patch: Apply one 7 mg, 14 mg, or 21 mg/24 hour patch daily. Lozenge: 2 mg or 4 mg lozenge dissolved in mouth every 1-2 hours, maximum 20 lozenges/day. Inhaler: 6-16 cartridges/day. Nasal spray: 1-2 doses/hour, maximum 40 doses/day. All routes: typical duration 8-12 weeks.
Transdermal patch: 21 mg/24 hours applied to dry, non-hairy skin once daily; gum: 2-4 mg chewed as needed (max 24 pieces/day); lozenge: 2-4 mg dissolved as needed (max 20 lozenges/day); inhaler: 6-16 cartridges/day (each 4 mg delivered); nasal spray: 1-2 doses/hour (1 dose = 0.5 mg, 32 mg/day max).
Clinical Note
moderateNicotine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Nicotine."
Clinical Note
moderateNicotine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Nicotine."
Clinical Note
moderateNicotine + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Nicotine resulting in a loss in efficacy."
Clinical Note
moderateNone Documented
None Documented
The terminal elimination half-life of nicotine is approximately 2 hours. This short half-life necessitates frequent dosing or continuous delivery to maintain therapeutic levels. Cotinine, the major metabolite, has a half-life of 15-20 hours.
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); short half-life leads to frequent dosing to maintain therapeutic effects.
Nicotine is extensively metabolized in the liver, primarily to cotinine. Renal excretion accounts for 2-35% of nicotine elimination unchanged, depending on urine pH (acidic urine increases excretion). Biliary/fecal excretion is minimal (<5%). Total clearance is about 1 L/min, with renal clearance of about 100 mL/min.
Primarily hepatic metabolism (80-90%) to cotinine and nicotine-N-oxide; renal excretion of unchanged nicotine accounts for 5-10% in non-smokers and up to 30% in smokers with acidic urine; less than 2% excreted in feces via biliary elimination.
Category C
Category C
Smoking cessation aid
Smoking cessation aid
Nicotine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Nicotine."